The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | AMIGO-1: pemetrexed, amivantamab and lazertinib in metastatic EGFRm NSCLC
William William Jr., MD, Oncoclínicas, São Paulo, Brazil, shares findings from the single-arm AMIGO-1 (NCT05299125) study examining treatment intensification with pemetrexed, amivantamab and lazertinib in patients with metastatic EGRR-mutated (EGFRm) non-small cell lung cancer (NSCLC). The 18-month progression-free survival rate of around 66% was improved compared with a historical control of osimertinib alone and was numerically higher than in the MARIPOSA (NCT04487080) trial of amivantamab and lazertinib. The triplet showed a higher rate of toxicities, however this was reduced by the introduction of a cap of 8 cycles of pemetrexed. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
